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Abstract Purpose To evaluate the efﬁcacy of an outpatient protocol with vaginal misoprostol
to treat delayed miscarriage.
Methods Retrospective analysis of prospectively collected data on women medically
treated for missed abortion with an outpatient protocol. The inclusion criteria were:
ultrasound-based diagnosis of missed abortion with less than 10 weeks; no heavy
bleeding, infection, inﬂammatory bowel disease or misoprostol allergy; nomore than 2
previous spontaneous abortions; the preference of the patient regarding the medical
management. The protocol consisted of: 1) a single dose of 800 µg of misoprostol
administered intravaginally at the emergency department, after which the patients
were discharged home; 2) clinical and ultrasonographic evaluation 48 hours later – if
the intrauterine gestational sac was still present, the application of 800 µg of vaginal
misoprostol was repeated, and the patients were discharged home; 3) clinical and
ultrasonography evaluation 7 days after the initiation of the protocol – if the
intrauterine gestational sac was still present, surgical management was proposed.
The protocol was introduced in January 2012. Every woman received oral analgesia and
written general recommendations. We also gave them a paper form to be presented
and ﬁlled out at each evaluation.
Results Complete miscarriage with misoprostol occurred in 340 women (90.2%).
Surgery was performed in 37 (9.8%) patients, representing the global failure rate of the
protocol. Miscarriage was completed after the ﬁrst misoprostol administration in
208 (55.2%) women, with a success rate after the second administration of 78.1%
(132/169). The average age of the women with complete resolution using misoprostol
was superior to the average age of those who required surgery (33.99 years versus
31.74 years; p ¼ 0.031). Based on the ultrasonographic ﬁndings in the ﬁrst evaluation,
the women diagnosed with fetal loss achieved greater success rates compared with
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Non-viableﬁrst trimester intrauterine pregnancy is themost
common complication of early pregnancy. It accounts for 20%
of all pregnancies,1 and may present as delayed miscarriage
(fetal loss and empty sac), spontaneous or incomplete mis-
carriage. The approach to early pregnancy failure can be
either surgical (dilation and suction curettage), medical
(with misoprostol or mifepristone) or expectant.
Traditionally, the surgical treatment was the ﬁrst option
in cases of incomplete and delayed miscarriage. Moreover,
we have now evidence that supports more conservative
approaches to early pregnancy loss, namely medical treat-
ment and expectant management.2,3 In a meta-analysis in
which medical treatment was compared with expectant
management, the former was 2.77-foldmore likely to induce
complete evacuation of conception products.4
Over the years, many studies observed the efﬁcacy and
acceptance of misoprostol as a treatment option for incom-
plete and delayed miscarriage,3,5,6 and as an option in
outpatient management protocols, with success rates rang-
ing from 77.3% to 92.7%.5,7–9
The efﬁcacy of themedical treatment with prostaglandins
depends on both the dose and route of administration.
Hence, the vaginal administration of misoprostol seems to
be more effective than the oral administration, and has less
side effects.10
The aim of this study was to evaluate the efﬁcacy of an
outpatient protocol for the medical management of delayed
miscarriage with vaginal misoprostol.
Methods
Patient Selection and Outpatient Protocol
We performed a retrospective analysis of the women medi-
cally treated with misoprostol for delayed miscarriage (fetal
loss and empty sac) in an outpatient protocol. Data was
collected prospectively using a paper form that was pre-
sented and ﬁlled out at each evaluation.
The women enrolled in this study were diagnosed either
occasionally on a routine ultrasound scan, or when they were
admitted to the emergency department because of early
bleeding in pregnancy. The ultrasound ﬁndings considered
Conclusions We conclude this is an effective and safe option in the majority of
delayed miscarriage cases during the ﬁrst trimester, reducing surgical procedures and
their consequences.
Resumo Objetivo Avaliar a eﬁcácia de um protocolo de tratamento médico da gravidez
inviável do primeiro trimestre (GI1°T) com misoprostol vaginal em regime de
ambulatório.
Métodos Análise retrospectiva de dados colhidos prospectivamente de grávidas
tratadas com misoprostol vaginal em ambulatório. Os critérios de inclusão foram:
diagnóstico de GI1°T com < 10 semanas de gestação; ausência de hemorragia
abundante, infeção, doença inﬂamatória intestinal ou alergia ao misoprostol;  2
abortamentos anteriores; e preferência da paciente por tratamento médico. O
protocolo consiste em: dia 0–aplicação de misoprostol intravaginal (800µg) no Serviço
de Urgência e alta para o domicílio; dia 2–se persistência de saco gestacional
intrauterino, aplicação de segunda dose de misoprostol (800µg) e alta; Dia 7–se
persistência de saco gestacional intrauterino, proposto esvaziamento uterino instru-
mentado. O protocolo foi implementado em janeiro de 2012. Todas as grávidas
receberam analgesia oral e informação por escrito com recomendações gerais.
Receberam ainda um formulário a ser preenchido em cada vinda à urgência.
Resultados Das 377 mulheres incluídas, observou-se abortamento completo em 340
(90,2%). As restantes 37 (9,8%) necessitaram de tratamento cirúrgico – taxa de falência
global do protocolo. Em 208 (55,2%), o sucesso foi observado ao ﬁm da 1ª dose, com
uma taxa de eﬁcácia da 2ª dose de 78,1% (132/169). A idade média das mulheres com
sucesso do tratamento médico foi superior à das mulheres sem sucesso do mesmo
(33,99 versus 31,74 anos; p ¼ 0,031). O sucesso do tratamento foi maior quando o
diagnóstico ecográﬁco inicial era de um embrião sem vitalidade comparado com os
casos de ovo anembrionado (p ¼ 0.049).
Conclusões Conclui-se que esta é uma opção de tratamento eﬁcaz e segura na
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necessary for the diagnosis of delayedmiscarriagewere one of
the following: an irregular intrauterine gestational sac with
 25 mm of diameter and no embryo and/or no yolk sac; an
intrauterine gestational sac or an embryo with an abnormal
growth upon ultrasound over a minimum of one week; or an
intrauterine gestational sac with an embryo with a crown-
rump length  7 mm and no cardiac activity observed.
The inclusion criteriawere: ultrasound-based diagnosis of
delayed miscarriage with gestational age based on ultra-
sound fetal measurement < 10 weeks; no heavy bleeding;
no signs of infection; no more than 2 previous spontaneous
miscarriages; no history of misoprostol allergy; no history of
inﬂammatory bowel disease; and the preference of the
patient regarding the medical management. For patients
with delayed miscarriage with 10 weeks of gestation or
with 2 or more previous spontaneous miscarriage, inpatient
management was recommended.
The women meeting these criteria were treated according
to the following outpatient protocol: a single dose of 800 µg of
misoprostol administered intravaginally at the emergency
department, after which the patients were discharged
home; clinical and ultrasonography evaluation 48 hours later
and, if the intrauterine gestational sac was still present,
a second dose of 800 µg of misoprostol was administered
intravaginally, and the patients were discharged home – if no
gestational sac was observed, no further evaluation was
performed; clinical and ultrasonographic evaluation 7 days
after the initiation of the protocol for those who received
a second dose of misoprostol – if the intrauterine gestational
sacwas still present, surgicalmanagementwasproposed. Oral
analgesia was prescribed to every woman, and they received
written general recommendations. They were instructed to
return if any of the following symptoms occurred: heavy
vaginal bleeding, intense vomiting, abdominal cramps, or
temperature > 38.5°C. The patients also received a paper
form to be presented and ﬁlled out at each evaluation.
If any of the following clinical ﬁndings were present,
the women were considered not eligible to enroll on the
protocol: exuberant vaginal bleeding and/or hemoglobin
< 10 mg/dL; signs or symptoms of infection; inﬂammatory
bowel disease; allergy to misoprostol; recurrent miscar-
riages; and ultrasound suspicion of gestational trophoblastic
disease or ectopic pregnancy.
The criterion used to document success after the medical
management was the absence of the gestational sac upon
transvaginal ultrasound.
Written informed consent was not required because this
protocol was introduced in our department as a routine
standard practice. The present study was approved by our
ethics committee.
Evaluated Outcomes
The main outcome evaluated was the global success rate of
this protocol, represented by women achieving a complete
miscarriage with the medical treatment. The success of the
protocol was deﬁned by the absence of the gestational sac
upon a transvaginal ultrasound evaluation. We also analyzed
the success rate achieved with each misoprostol application.
Statistical Analysis
The statistical signiﬁcance was determined for the categori-
cal variables with the Chi-squared (χ2) test, and for the
continuous variables, we used standard parametric tests;
p < 0.05 considered statistically signiﬁcant. The Statistical
analysis was performed using the Statistical Package for The
Social Sciences (IBM SPSS Statistics, IBM Corp., Armonk, NY,
US) software, version 21.0.
Results
A total of 377womendiagnosedwith delayedmiscarriagemet
the inclusion criteria and were elected to enroll on this
outpatient protocol. The average age of the women enrolled
was 33.8 years.We obtained information about parity regard-
ing 321 women: 167 (52%) were nulliparous, 135 women
(42.1%)were in theirﬁrst pregnancy, and32 (10%) had already
had at least 1 previous abortion, spontaneous or not. The
remaining 154 (48%) had had at least one live birth. According
to the ultrasonographic criteria, 23.5% were diagnosed with
empty sac, with a mean diameter of 23 mm, and 76.5% were
diagnosed with fetal loss, with a mean crown-rump length
(CRL) of 12 mm. The women diagnosed with fetal loss were
older (34.12 years versus32.64years,p ¼ 0.048) than theones
diagnosed with empty sac (►Table 1).
Complete miscarriage with the medical treatment was
observed in 340 (90.2%) women. Surgical treatment was
performed in the remaining 37 women (9.8%), representing
the global failure rate of the medical treatment (►Table 2).
Themiscarriagewas complete after theﬁrst administration
ofmisoprostol in 208 (55.2%)women, with a success rate after
the second administration of 78.1% (132/169) (►Table 2).
The mean age of the women who achieved complete
resolution with the medical treatment was superior to
the mean age of those who required surgical procedures
(33.99 years versus 31.74 years; p ¼ 0.031) (►Table 3). The
success of the medical treatment was not different between
nulliparous and multiparous women (p ¼ 0.732).
According to the ultrasonographic ﬁndings in the ﬁrst eval-
uation, the women diagnosed with fetal loss achieved greater
success rates with themedical treatment when comparedwith
those diagnosed with empty sac (p ¼ 0.049) (►Table 3).
The mean diameter of the gestational sac and the mean CRL
Table 1 Study population characteristics
Median age (years) ¼ 33.8
Nulliparous (n ¼ 321) n ¼ 167 (52%)
1st pregnancy n ¼ 135 (42.1%)
> 1 abortion n ¼ 32 (10%)
Parity  1 (n ¼ 321) n ¼ 154 (48%)
Empty sac (n ¼ 375) n ¼ 88 (23.5%)
Gestational sac diameter (mm) ¼ 23
Fetal loss (n ¼ 375) n ¼ 287 (76.5%)
Crown-rump length (mm) ¼ 12
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were not statistically different between the cases with and
without success of the medical treatment (23 mm versus
19 mm, p ¼ 0.194; 12 mm and 13 mm, p ¼ 0.733 respective-
ly). Thisdifferencewasalsoobservedwhenconsideringonly the
ﬁrst administrationofmisoprostol (p ¼ 0.014), but thatwasnot
the case for the second administration of misoprostol.
In termsofcomplications thatmayarisefromthis approach,
wecouldobtain information from329cases (87.3%). Therewas
onecaseofmajor vaginal bleedingafter theﬁrstdoseofvaginal
misoprostol, which was treated with an emergency surgical
management (uterine aspiration), with no need of blood
transfusion to stabilize the patient. A case of infection treated
withsurgeryandoralantibioticswasdiagnosedoneweekafter
initiating the medical treatment during the second routine
visit to theemergencydepartment. Theevolutionofbothcases
was favorable, with no more complications observed, and a
global complication rate of 0.61%.
Discussion
Main Findings and Interpretation
In 2005, a study concluded that 400 µg of misoprostol self-
administered intravaginally every 4 hours, up to a maximum
dose of 1,200 µg, had a success rate of 91%, and it was a safe
treatment option.11 In the same year, the efﬁcacy, safety, and
acceptability of this treatment were assessed in a large,
randomized trial that concluded that treatment with 800 μg
of vaginalmisoprostol is a safe and acceptable approach,with a
success rate of 84%.6 Twoyears later, 75womenwere treated
fordelayedmiscarriagewith800µgofvaginalmisoprostol plus
2 additional doses of 400 µg each to take orally the following
day:77.3%of themachievedcompletemedical evacuationwith
this treatment.7 Recently, in April 2017, a comprehensive
reviewandmeta-analysis12 concluded that the administration
ofmisoprostol is an effectivemethod to solvemissed abortion,
and both 600 μg of sublingualmisoprostol or 800 μg of vaginal
misoprostolmay be good choices as aﬁrst dose. However, they
state that the ideal dose, medication interval, and the safety of
waiting at home need further research.
In this study, we present the results of an outpatient
protocol for the medical treatment of delayed miscarriage,
andweobserved success rates comparable to thoseof themost
recent studies on this topic. A 2012 study compared the
effectiveness and adverse effects of 800 µg and 600 µg of
vaginal misoprostol every 24 hours for 2 days in an outpatient
setting, with the authors concluding that 600 µg was as
effective as 800 µg in inducing complete uterus evacuation
after missed abortion (with success rates of 87.8% and 90.6%
respectively; p ¼ 0.18).5 Moreover, this proved to be a safe
treatment, with few adverse effects. Our success rate (90.2%),
which includes both women receiving doses of 800 µg and
1,600µg (if twodoseswere needed), is similar to that observed
in the literature with the same dose of misoprostol.5
Another study reported the prospective outcomes of the
medicalmanagement of delayedmiscarriage in anAustralian
cohort composed of 264women. Doses of 400 µg or 800 µg of
misoprostol were administered intravaginally, at presenta-
tion, and repeated the following day if the products of
conception were still there. With a success rate of 78%, this
was considered an effective, safe and acceptable treatment.8
The discrepancy observed between theirs and our results
may be explained by the success criteria used, as in their
study they used an endometrium thickness > 30 mm as an
indication for surgery.
More recently, in 2014, a randomized control trial with 154
women assessed the differences between outpatient and inpa-
tient treatments with vaginal misoprostol. Doses of 800 µg of
misoprostol were administered vaginally every 8 hours to a
maximumof3 doses. The overall success ratewas of 92.7%, and
a higher success was observed with the outpatient treatment
compared with the inpatient treatment, even though this was
not statistically signiﬁcant. Moreover, the side effects and
complications were similar between the two groups.9 The
higher success rate may be a consequence of the higher dose
of misoprostol (a total of 2,400 µg) administered within a
shorter interval.
Our results are consistentwithreports frompreviousstudies
in termsofeffectiveness. Thedifferencesobservedin thesuccess
ratemaybe, inpart, explainedby thecriteriaused to classify the
treatment as successful. In our study, we used absence of
gestational sac upon transvaginal ultrasound as the criterion
to document success after themedicalmanagement of delayed
miscarriage. This is associatedwith thehighest short- and long-
term success rates, and alsowithmild symptoms following the
Table 2 Resultsobserved for the treatmentofdelayedmiscarriage
with vaginal misoprostol in an outpatient setting
n %
Medical treatment (success) 340 90.2
After 1st dose of misoprostol 208 55.2
After 2nd dose of misoprostol 132 35
Surgery (treatment failure) 37 9.8
Table 3 Success and failure rates in treating delayed miscarriage
with vaginal misoprostol
Success Failure p
Maternal age ¼ 33.99 ¼ 31.74 0.031
Nulliparity
Nulliparous 150 (89.8%) 17 (10.2%) 0.732
Parity  1 141 (91.6%) 13 (8.4%)
Ultrasound ﬁndings
Empty sac 74 (84.1%) 14 (15.9%) 0.049
Fetal loss 264 (92%) 23 (8%)
Gestational sac
diameter (mm)
¼ 23 ¼ 19 0.194
Crown-rump
length (mm)
¼ 12 ¼ 13 0.733
Note: p < 0.05 were considered statistically signiﬁcant.
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treatment with vaginal misoprostol.13 However, other studies
used endometrial cavity < 15 mm thick as the criterion for
success.5,7,9,11 The occurrence of major side effects was rare
(0.61%), which is in agreement with previous ﬁndings that
consideredvaginalmisoprostol a safe treatment.8,14Wedidnot
collect informationabout the long-termsafetyof the treatment,
butaccording toastudya recentstudy,vaginalmisoprostoldoes
not impair future fertility.15
In this study we achieved a greater success rate with the
medical treatment among the women diagnosed with fetal
loss when compared with those diagnosed with empty sac.
Other researchers have also observed this difference and
suggested that it would be reasonable to divide ﬁrst trimes-
ter miscarriages into different groups according to the ultra-
sonography ﬁndings, because they have different success
rates.16
Strengths and Limitations
This study assessed the efﬁcacy of vaginal misoprostol for
ﬁrst trimester delayed miscarriage according to the protocol
described before. We also searched for adverse effects after
the initiation of the medical protocol, with only one case of
infection and one of vaginal bleeding leading to surgical
treatment. Our ﬁndings are concordant with previous stud-
ies that concluded for the safety of this drug when adminis-
tered vaginally, with only minor adverse effects (diarrhea,
nausea, fever and crampy abdominal pain), none of them
life-threatening. In the randomized control trial by Zhang
et al6, nauseawas observed in 53% of the sample, vomiting in
20%, diarrhea in 24%, and abdominal pain in 99%, with
hemorrhage and pelvic infection being rare (1% or less).
We did not have any case of gastrointestinal side effects,
and this may be due to the prophylactic prescription of
antiemetic drugs and painkillers.
Conclusion
In summary, our study shows that vaginal misoprostol for
the outpatient medical management of delayed miscarriage
is an effective and safe option in the majority of the cases,
reducing the number of women subjected to surgical pro-
cedures and the consequences of such an approach. More-
over, it combines the advantages of being performed in an
outpatient setting (with lesser costs and more comfort for
the patients), with the reassurance that the misoprostol
administration is performed by doctors, not depending on
the patients’ skills, and enabling an evaluation between the
administration of the doses of misoprostol.
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